Amends GS 90-85.3A to allow a pharmacist to order and perform a CLIA-waived test to: (1) assist with clinical decision making related to the use and monitoring of medications; and (2) treat influenza, pharyngitis caused by streptococcus, and other health conditions screened by using a CLIA-waived test. Defines CLIA-waived test as a lab test approved by the FDA and determined by the Centers for Medicare and Medicaid Services to qualify for a waiver under the federal Clinical Laboratory Improvement Amendments of 1988 and safe for use in non-laboratory settings. Effective October 1, 2022.
|View NCGA Bill Details||2021|
AN ACT TO ALLOW PHARMACISTS TO TEST AND TREAT FOR CERTAIN ILLNESSES WITH CERTAIN MEDICATIONS APPROVED BY THE BOARD OF PHARMACY, TO PROVIDE FOR FAIR AND EQUITABLE REIMBURSEMENT OF HEALTH CARE SERVICES OR PROCEDURES THAT ARE PERFORMED BY A PHARMACIST WITHIN THAT PHARMACIST'S SCOPE OF PRACTICE AND THAT ARE EQUIVALENT TO SERVICES PERFORMED BY OTHER HEALTH CARE PROFESSIONALS, AND TO APPROPRIATE FUNDS TO THE DEPARTMENT OF INSURANCE.Intro. by Burgin.
No bill history found
Bill S 885 (2021-2022)Summary date: May 27 2022 - View Summary